ArticleInternational journal of hematology2026
Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, nonrandomized clinical trial.Research and practice in thrombosis and haemostasis · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundvon Willebrand disease (VWD) is a hereditary bleeding disorder caused by quantitative or qualitative deficiencies in von Willebrand factor (VWF). Our previous studies demonstrated that emicizumab, a bispecific monoclonal antibody that mimics activated factor VIII (FVIII) cofactor activity, enhances thrombus formation under high-shear conditions in whole blood from patients with VWD (PwVWD). However, its effect on plasma coagulation potential remains unclear.
aimTo evaluate the coagulation-enhancing effect of emicizumab in plasma samples from PwVWD using global coagulation assays.
methodsPlasma samples from PwVWD (type 1, n = 4; type 2, n = 9; type 3, n = 3) were spiked with emicizumab (50 or 100 µg/mL), recombinant VWF (rVWF; 2.4 U/mL), or plasma-derived FVIII/VWF concentrate (pd-FVIII/VWF; 1/2.4 U/mL). Coagulation potential was assessed using clot waveform analysis (Ad|min1|) and thrombin generation assay (Peak-Th).
resultsEmicizumab dose-dependently increased Ad|min1| in all type 1 VWD samples and improved Peak-Th in two cases. In type 2 VWD, Ad|min1| increased in all samples, while Peak-Th improved in six cases. In type 3 VWD, emicizumab increased both parameters in all cases.
conclusionEmicizumab enhanced ex vivo coagulation potential in plasma samples from PwVWD across all subtypes, supporting its potential as a therapeutic option.
Indexed as
Identifiers
41217634What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.